Extract from M&A Insights

The below story was originally featured in our daily M&A Insights Newsletter. Selected stories, including this one, are posted to our website with some weeks of delay.
Galecto Biotech raises DKK 590m from international investor group
October 26, 2018

The Danish Biotech company failed to exit to Bristol-Myers Squibb in late 2017 but has now raised DKK 590m from existing and new investors. Novo Seeds is the largest stakeholder and the new investors are a.o. American-based Orbimed and Spanish-based venture fund Ysios Capital. Prior to the capital raise, Galecto had received DKK 75m in funding.

ⓘ This story was originally featured in our daily M&A Insights newsletter.
Our insights have been covered by: